Evoke Pharma (EVOK) Misses Q3 EPS by 14c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Evoke Pharma Reports Third Quarter 2017 Results and Highlights
November 14, 2017 4:05 PM ESTAnnounced positive topline results from comparative exposure pharmacokinetic (PK) trial for Gimoti505(b)(2) New Drug Application (NDA) submission on track for Q1 2018 filingPartnered with the Patheon division of Thermo Fisher Scientific Inc. as a commercial manufacturing partner for Gimoti$10.4M in cash and extended estimated cash runway now through June 2018
SOLANA BEACH, Calif., Nov. 14, 2017 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the third quarter ended September... More
